Protocol Ledger

NCT04102111 · Phase II · TERMINATED

A Study Evaluating Participants With Moderately to Severely Active Crohn's Disease

Interventional Phase II clinical trial protocol NCT04102111 sponsored by Johnson & Johnson / Janssen in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-09-23 Enrollment: 48 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04102111
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)48 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04102111
Protocol FieldVerified Registry Value
NCT IdentifierNCT04102111
Consolidated Lead SponsorJohnson & Johnson / Janssen
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment48 participants (ACTUAL)
Registered Start Date2019-09-23
WhyStopped ClassificationLack of Efficacy / Futility

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04102111
Hospital Research SiteLocationSite Profile
Washington University and Siteman Cancer CenterSaint Louis, MOOpen Hospital Dossier ->
Columbia University Irving Medical CenterNew York, NYOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Johnson & Johnson across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI